Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data
Bausch + Lomb's chief executive change and Merck's newly released data for its experimental eye drug in diabetic macular edema headline this roundup of the day's industry news.
Bausch + Lomb
Global eye health company developing, manufacturing and marketing vision care products, contact lenses, ophthalmic pharmaceuticals and surgical devices.
Company Info
Upcoming Milestones & Key Dates
2026-Q4
Clinical
Dry eye combo Phase 3 data readout
2027-Q1
Regulatory
Potential EU filing for dry eye combo
Clinical Development Pipeline
NOV03
Target: Meibomian glandsLumify
Target: Alpha-adrenergic agonistBrimonidine/Brinzolamide
Target: Alpha-2 agonist/CAIRecent News
Bausch + Lomb CEO Brent Saunders hits the exit again
Bausch + Lomb is replacing chief executive Brent Saunders, who is leaving the eye-care company for a second time, and has named an interim successor to lead the business.
FDA warning letter accuses Bausch & Lomb of lacking commitment to remediation
After reviewing Bausch & Lomb’s response to its observations, the FDA questioned whether the company is committed to implementing significant design remediations.
Leadership Team
Brent Saunders
Chairman and CEO
Sam Eldessouky
CFO
Joe Gordon
President, Global Vision Care